Aakaar Medical Technologies IPO is a book-built issue IPO, aiming to raise ₹27.00 crore. It is an entirely a fresh issue of 37.50 lakh shares. The bidding window was open from June 20, 2025, to June 24, 2025, with the IPO allotment to be finalised tomorrow on June 25, 2025. Aakaar Medical Technologies is scheduled to list on NSE SME on June 27, 2025.
The IPO was priced at a range of ₹68 – ₹72 per share with a lot size of 1600 shares. The public issue received bids for 57,00,800 shares against 24,96,000 shares available, resulting in an overall subscription of 2.28 times. QIBs NIIs led the response, subscribing 3.51 times their quota, followed by retail investors at 1.93 times.
Aakaar Medical Technologies' ₹27.00 crore IPO, priced between ₹68 – ₹72 per share, was subscribed 2.28 times overall. The IPO is an entirely a fresh issue of 37.50 lakh shares. Bidding took place from June 20 to June 24, 2025, with the Aakaar Medical Technologies IPO allotment status on June 25, 2025. Retail investors subscribed 1.93 and NIIs 1.48 times. Listing is expected on June 27, 2025.
The table below breaks down the Aakaar Medical Technologies share allocation for different categories, highlighting the number of shares and their percentage of the total issue. However, the key focus remains on the quotas allocated to retail investors and HNIs, as they are the most relevant for individual investors.
| Investor Category | Shares Offered |
| Market Maker Shares Offered | 1,88,800 (4.79%) |
| Anchor Investor Shares Offered | 1,88,800 (4.79%) |
| QIB (Ex. Anchor) Shares Offered | 7,12,000 (18.07%) |
| NII (HNI) Shares Offered | 5,36,000 (13.60%) |
| Retail Shares Offered | 12,48,000 (31.67%) |
| Total Shares Offered | 39,40,800 (100.00%) |
Data Source: NSE
| Category | Subscription (times) |
| Qualified Institutional Buyers | 3.51 |
| Non-Institutional Investors | 1.48 |
| Retail Individual Investors | 1.93 |
| Total shares | 2.28 |
Note: The subscription details are as of June 24, 2025
Aakaar Medical Technologies Limited, founded in 2013 by Mr. Dilip Meswani, is a prominent player in the Indian medical aesthetics and cosmetic devices space. With over 25 years of experience in the aesthetic industry, Mr. Meswani transitioned his earlier proprietary business into this company to strengthen its market presence.
Aakaar focuses on business-to-business (B2B) distribution, catering to dermatologists, plastic surgeons, and aesthetic physicians across India. The company offers a diverse portfolio of medical aesthetic products, including its own brands—both domestically produced and internationally sourced—and reputed imported brands from countries like Korea, Spain, Italy, and Austria.
In FY2025, imported brands accounted for 62.28% of revenue, while own-branded products contributed 37.72%. Own-brand aesthetic products are developed through third-party or loan licensing manufacturing arrangements, while aesthetic devices are either sourced domestically or imported.
The company actively engages in product research, market trend analysis, and concept development through a well-structured ideation process. Aakaar relies on its experienced team to co-develop formulations and prototypes with its partners.
Know more about IPO allotment status and check your application details online for the latest updates on share allocation.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jun 24, 2025, 7:42 PM IST
Akshay Shivalkar
Akshay Shivalkar is a financial content specialist who strategises and creates SEO-optimised content on the stock market, mutual funds, and other investment products. With experience in fintech and asset management, he simplifies complex financial concepts to help investors make informed decisions through his writing.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
